doi: 10.3390/biology10090891
In the AWARD-7 trial (which was not a CVOT) performed in T2DM subjects with moderate-to-severe CKD, once-weekly dulaglutide produced glycemic control similar to that achieved with insulin glargine, but showed evidence of reduced decline in eGFR (64)
Repeated compression of the dosing interval increases your average drug exposure beyond what was prescribed, elevates side effect risk, and disrupts the steady-state pharmacokinetics that your body has adapted to
In the last couple of years, the drug has grown rapidly in popularity among non-diabetes patients as a weight loss drug
Vaccinations: 21 days after hepatitis B or combination Hepatitis B and A vaccines (Heptavax, Energix, Recombivax), 4 weeks after MMR, Chickenpox (Varivax)